A detailed history of State Street Corp transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, State Street Corp holds 10,352,356 shares of RXRX stock, worth $77.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,352,356
Previous 12,151,646 14.81%
Holding current value
$77.6 Million
Previous $120 Million 13.86%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$9.13 - $15.52 $16.4 Million - $27.9 Million
-1,799,290 Reduced 14.81%
10,352,356 $103 Million
Q4 2023

Feb 14, 2024

BUY
$5.09 - $10.79 $2.01 Million - $4.26 Million
394,558 Added 3.36%
12,151,646 $120 Million
Q3 2023

Nov 14, 2023

BUY
$6.59 - $15.86 $39.9 Million - $96.1 Million
6,059,156 Added 106.34%
11,757,088 $89.9 Million
Q2 2023

Aug 14, 2023

SELL
$4.56 - $9.94 $3.08 Million - $6.71 Million
-674,583 Reduced 10.59%
5,697,932 $42.6 Million
Q1 2023

May 15, 2023

SELL
$6.42 - $9.64 $9.62 Million - $14.4 Million
-1,498,443 Reduced 19.04%
6,372,515 $42.5 Million
Q4 2022

Feb 14, 2023

BUY
$7.16 - $12.7 $23.7 Million - $42.1 Million
3,315,199 Added 72.77%
7,870,958 $60.7 Million
Q3 2022

Nov 15, 2022

BUY
$7.83 - $13.6 $19 Million - $33 Million
2,430,027 Added 114.31%
4,555,759 $48.5 Million
Q2 2022

Aug 15, 2022

BUY
$5.04 - $9.26 $1.04 Million - $1.92 Million
206,998 Added 10.79%
2,125,732 $17.3 Million
Q1 2022

May 16, 2022

SELL
$6.16 - $18.03 $16.9 Million - $49.4 Million
-2,737,993 Reduced 58.8%
1,918,734 $13.7 Million
Q4 2021

Feb 14, 2022

BUY
$16.14 - $21.86 $48.6 Million - $65.8 Million
3,012,233 Added 183.17%
4,656,727 $79.8 Million
Q3 2021

Nov 15, 2021

BUY
$19.03 - $41.33 $24.1 Million - $52.4 Million
1,267,062 Added 335.71%
1,644,494 $37.8 Million
Q2 2021

Aug 16, 2021

BUY
$18.0 - $37.42 $6.79 Million - $14.1 Million
377,432 New
377,432 $13.8 Million

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.35B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.